Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 1
1999 1
2009 1
2011 1
2012 1
2017 1
2018 1
2019 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
The following terms were not found in PubMed: RP1-41C23.1, RP1-41C23.1
Page 1
Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists.
Fromm G, de Silva S, Schreiber TH. Fromm G, et al. Front Immunol. 2023 Sep 19;14:1236332. doi: 10.3389/fimmu.2023.1236332. eCollection 2023. Front Immunol. 2023. PMID: 37795079 Free PMC article. Review.
TNF receptor homotrimers are natively activated by similarly homo-trimerized TNF ligands, but can also be activated by synthetic agonists including engineered antibodies and Fc-ligand fusion proteins. A large body of literature from pre-clinical models supports the hypothe …
TNF receptor homotrimers are natively activated by similarly homo-trimerized TNF ligands, but can also be activated by synthetic agonists in …
Activation of the DR3-TL1A Axis in Donor Mice Leads to Regulatory T Cell Expansion and Activation With Reduction in Graft-Versus-Host Disease.
Mavers M, Simonetta F, Nishikii H, Ribado JV, Maas-Bauer K, Alvarez M, Hirai T, Turkoz M, Baker J, Negrin RS. Mavers M, et al. Front Immunol. 2019 Jul 17;10:1624. doi: 10.3389/fimmu.2019.01624. eCollection 2019. Front Immunol. 2019. PMID: 31379829 Free PMC article.
Death receptor 3 (DR3) is a tumor necrosis factor receptor superfamily member (TNFRSF25), which is minimally expressed on resting conventional T cells (though readily inducible upon cell activation), yet highly expressed on resting FoxP3(+) regulatory T cells (Treg). ...Ho …
Death receptor 3 (DR3) is a tumor necrosis factor receptor superfamily member (TNFRSF25), which is minimally expressed on resting con …
Death receptor 3 signaling enhances proliferation of human regulatory T cells.
Bittner S, Knoll G, Ehrenschwender M. Bittner S, et al. FEBS Lett. 2017 Apr;591(8):1187-1195. doi: 10.1002/1873-3468.12632. Epub 2017 Apr 10. FEBS Lett. 2017. PMID: 28337757 Free article.
Here, we show that human Tregs express DR3 and demonstrate DR3-mediated activation of p38, ERK, and NFkappaB. ...In summary, our results establish a functional role for DR3 signaling in human Tregs and could potentially help to tailor Treg-based therapies....
Here, we show that human Tregs express DR3 and demonstrate DR3-mediated activation of p38, ERK, and NFkappaB. ...In summary, our resu …
Very Low Numbers of CD4+ FoxP3+ Tregs Expanded in Donors via TL1A-Ig and Low-Dose IL-2 Exhibit a Distinct Activation/Functional Profile and Suppress GVHD in a Preclinical Model.
Copsel S, Wolf D, Kale B, Barreras H, Lightbourn CO, Bader CS, Alperstein W, Altman NH, Komanduri KV, Levy RB. Copsel S, et al. Biol Blood Marrow Transplant. 2018 Sep;24(9):1788-1794. doi: 10.1016/j.bbmt.2018.04.026. Epub 2018 May 8. Biol Blood Marrow Transplant. 2018. PMID: 29751114 Free PMC article.
We have recently reported a novel approach that induces the marked expansion and selective activation of Tregs in vivo by targeting tumor necrosis factor receptor superfamily 25 (TNFRSF25) and CD25. A potential advance to promote clinical application of Tregs to ameliorate …
We have recently reported a novel approach that induces the marked expansion and selective activation of Tregs in vivo by targeting tumor ne …
Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.
Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. Emery JG, et al. J Biol Chem. 1998 Jun 5;273(23):14363-7. doi: 10.1074/jbc.273.23.14363. J Biol Chem. 1998. PMID: 9603945 Free article.
Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B.
Marsters SA, Sheridan JP, Donahue CJ, Pitti RM, Gray CL, Goddard AD, Bauer KD, Ashkenazi A. Marsters SA, et al. Curr Biol. 1996 Dec 1;6(12):1669-76. doi: 10.1016/s0960-9822(02)70791-4. Curr Biol. 1996. PMID: 8994832 Free article.
In addition, Apo-3 resembles TNFR1 and CD95 in that it contains a cytoplasmic death domain. The Apo-3 gene mapped to human chromosome 1p36.3, and Apo-3 mRNA was detected in several human tissues, including spleen, thymus, peripheral blood lymphocytes, small intestin …
In addition, Apo-3 resembles TNFR1 and CD95 in that it contains a cytoplasmic death domain. The Apo-3 gene mapped to human chromosome …
Enhanced wound healing by recombinant Escherichia coli Nissle 1917 via human epidermal growth factor receptor in human intestinal epithelial cells: therapeutic implication using recombinant probiotics.
Choi HJ, Ahn JH, Park SH, Do KH, Kim J, Moon Y. Choi HJ, et al. Infect Immun. 2012 Mar;80(3):1079-87. doi: 10.1128/IAI.05820-11. Epub 2011 Dec 19. Infect Immun. 2012. PMID: 22184415 Free PMC article.
The study was focused on the use of the safe probiotic E. coli Nissle 1917, which was constructed to secrete human EGF in conjunction with the lipase ABC transporter recognition domain (LARD). ...The present study provides a basis for the clinical application of human …
The study was focused on the use of the safe probiotic E. coli Nissle 1917, which was constructed to secrete human EGF in conjunction …
Targeting lymphotoxin-mediated negative selection to prevent prostate cancer in mice with genetic predisposition.
Zhou P, Fang X, McNally BA, Yu P, Zhu M, Fu YX, Wang L, Liu Y, Zheng P. Zhou P, et al. Proc Natl Acad Sci U S A. 2009 Oct 6;106(40):17134-9. doi: 10.1073/pnas.0905707106. Epub 2009 Sep 23. Proc Natl Acad Sci U S A. 2009. PMID: 19805094 Free PMC article.
We show that targeted mutation of the lymphotoxin alpha (LTalpha) gene efficiently rescued tumor-reactive T cells, drastically reduced cancer incidence, and almost completely ablated metastasis. Remarkably, short-term treatments with the fusion protein consisting of consta …
We show that targeted mutation of the lymphotoxin alpha (LTalpha) gene efficiently rescued tumor-reactive T cells, drastically reduced cance …